In this pilot investigation we tried to detect possible association of plasma OPN and VEGF with myeloma related clinical manifestations such as anemia, renal dysfunction, and bone disease, as well as with serum beta-2 microglobulin and Durie-Salmon clinical stage which are prognosticators related to tumour burden. The gene discussed is B2M; the disease is anemia (phenotype).